Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

Adverse Prognostic Factors in Adult Secondary Hemophagocytic Lymphohistiocytosis: Results from Two Tertiary Academic Centers

Omar Abughanimeh, MD, Ayman Qasrawi, MD, James O. Armitage, MD, Julie M. Vose, MD MBA, Gerhard C. Hildebrandt, MD, Muhamed Baljevic, MD

Blood (2020) 136 (Supplement 1): 18–19.

https://doi.org/10.1182/blood-2020-137038

Published: 2020

Journal Articles

Enhancing Anti-Tumor Immunity and Responses to Immune Checkpoint Blockade By Suppressing Interleukin-10 in Chronic Lymphocytic Leukemia

Jacqueline R. Rivas, PhDBS, Sara S. Alhakeem, PhD, Joseph M. Eckenrode, PhD, Yinan Zhang, PhD, James P. Collard, BS, Gerhard C. Hildebrandt, MD, Roger A. Fleischman, MD PhD, Li Chen, PhD, Jon S. Thorson, PhD, Markos Leggas, PhD, Subbarao Bondada, PhD

Blood (2019) 134 (Supplement_1): 5486.

https://doi.org/10.1182/blood-2019-127178

Published: 2019

Journal Articles

Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study

Alison R. Sehgal, MD, John Godwin, John Pribble, Lei Wang, PhD, Jerill Thorpe, BSc, Gerhard C. Hildebrandt, MD

Blood (2019) 134 (Supplement_1): 2882.

https://doi.org/10.1182/blood-2019-127658

Published: 2019

Journal Articles

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Carlos R. Bachier, MD, Maria Lia Palomba, MD, Jeremy S. Abramson, MD MMSc, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, John Godwin, Gerhard C. Hildebrandt, MD, Tanya Siddiqi, MD, Don Stevens, MD, Thalia Farazi, Ana Kostic, Nikolaus S. Trede, Lei Wang, PhD, James Lymp, PhD, Tennille Thelen, Ken Ogasawara, David G. Maloney, MD PhD

Blood (2019) 134 (Supplement_1): 2868.

https://doi.org/10.1182/blood-2019-127566

Published: 2019

Journal Articles

Disparities in Plasma Cell Neoplasms in Kentucky, Appalachia and Other States: A Population Based Study

Ayman Qasrawi, MD, Richard L O'Neal, MD, Maxwell M. Krem, MD PhD, Gregory Monohan, MD, Reinhold Munker, MD, Gerhard C. Hildebrandt, MD

Blood (2019) 134 (Supplement_1): 4735.

https://doi.org/10.1182/blood-2019-127687

Published: 2019

Journal Articles

Neutralization of Macrophage Migration Inhibitory Factor (MIF) Reduces GVHD but Preserves GVL.

Sandra Miklos, Dipl., Biol., Gunnar Mueller, Petra Lindner, PhD, Ya-Yi Chang, MS, Ernst Holler, MD PhD, Richard Bucala, MD PhD, Gerhard C. Hildebrandt, MD

Blood (2007) 110 (11): 3234.

https://doi.org/10.1182/blood.V110.11.3234.3234

Published: 2007

Journal Articles

Critical Role for CCR1:CCL5 (RANTES) Receptor Ligand Interactions in Modulating Allogeneic T Cell Responses Following Bone Marrow Transplantation.

Sung Won Choi, MD, Gerhard C. Hildebrandt, MD, Ines Silva, Krystyna M. Olkiewicz, Stephen W. Chensue, MD, Chen Liu, MD, Meghana Chaudhary, Jacki Fisher, Thomas E. Lane, Kenneth R. Cooke

Blood (2005) 106 (11): 3107.

https://doi.org/10.1182/blood.V106.11.3107.3107

Published: 2005

Journal Articles

CCR1 Expression on Donor Leukocytes Is Critical to the Development of Graft Versus Host Disease after Allogeneic SCT.

Gerhard C. Hildebrandt, MD, Sung Choi, MD, Krystyna M. Olkiewicz, MS, Stephen W. Chensue, MD, Chen Liu, MD, Kenneth R. Cooke, MD

Blood (2004) 104 (11): 3067.

https://doi.org/10.1182/blood.V104.11.3067.3067

Published: 2004

Journal Articles

IL-13 - Predictor of or Protector from Acute Graft Versus Host Disease?.

Gerhard C. Hildebrandt, MD, Krystyna M. Olkiewicz, MS, Sung Choi, MD, Leigh A. Corrion, BS, Chen Liu, MD, Andrew N. McKenzie, MD, Kenneth R. Cooke, MD

Blood (2004) 104 (11): 3070.

https://doi.org/10.1182/blood.V104.11.3070.3070

Published: 2004

NARROW

Adverse Prognostic Factors in Adult Secondary Hemophagocytic Lymphohistiocytosis: Results from Two Tertiary Academic Centers

Enhancing Anti-Tumor Immunity and Responses to Immune Checkpoint Blockade By Suppressing Interleukin-10 in Chronic Lymphocytic Leukemia

Lisocabtagene Maraleucel (liso-cel) for Treatment of Second-Line Transplant Noneligible (TNE) Relapsed/Refractory (R/R) Aggressive Non-Hodgkin Lymphoma (NHL): Initial Results from the PILOT Study

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Disparities in Plasma Cell Neoplasms in Kentucky, Appalachia and Other States: A Population Based Study

Neutralization of Macrophage Migration Inhibitory Factor (MIF) Reduces GVHD but Preserves GVL.

Critical Role for CCR1:CCL5 (RANTES) Receptor Ligand Interactions in Modulating Allogeneic T Cell Responses Following Bone Marrow Transplantation.

CCR1 Expression on Donor Leukocytes Is Critical to the Development of Graft Versus Host Disease after Allogeneic SCT.

IL-13 - Predictor of or Protector from Acute Graft Versus Host Disease?.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only